中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

IND Application for Simcere’s Independently Developed Anti-TNFR2 Antibody Accepted by CDE

On October 8th, Simcere Pharmaceutical Group (2096.HK), announced that the clinical trial application for its independently developed SIM0235 (SIM1811...

2021-10-14
Envafolimab in Combination with Lenvatinib for the Treatment of Endometrial Cancer Granted Implied License for Clinical Trials

On September, 14, Simcere Pharmaceutical Group Limited (2096.HK) announced that the clinical trials application for Envafolimab in combinati...

2021-09-15
Latest Study Data of Sanbexin® Released at ESOC 2021

The 7th European Stroke Conference (ESOC), held online from 1 - 3 September 2021, is the leading forum in Europe for advances in research and clinic...

2021-09-03
Simcere Pharmaceutical Group Announces 2021 Interim Results | Solid Revenue Growth Driven by Sanbexin®, and Rapid Progress in Innovative R&D

On August 26, 2021, Simcere Pharmaceutical Group Co., Ltd. (HKEX: 2096) released announcement of 2021 Interim Results.In the first half of 2021, the c...

2021-08-27
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666 Fax：025-85262330

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.